The round was led by Leaps by Bayer with participation from Illumina Ventures, SVG Thrive, Congruent Ventures, and Endeavor8. The round will accelerate the commercial launch of engineered microbial biopesticides combatting fungal diseases in soybeans and specialty crops in the United States, making these biologicals economically viable without sacrificing performance. The round will also support Robigo's pipeline expansion to target additional soil-borne pathogens in broadacre crops, tapping into an addressable market of $10 billion.

Robigo is crop protection without compromise. Powered by its proprietary ARGO™ platform, Robigo engineers biological solutions that outperform synthetic chemistries while delivering healthier soils and supporting a more resilient food system.